Journal article
Hyperprogressive disease in advanced cancer patients treated with nivolumab: a case series study
Anti-cancer drugs, Vol.31(2), pp.190-195
02/01/2020
DOI: 10.1097/CAD.0000000000000864
PMID: 31850916
Abstract
The aim of this retrospective study was to detail the main clinicopathological characteristics of advanced cancer patients exhibiting hyperprogressive disease (HPD) during immune checkpoint inhibitor (ICI) nivolumab as second- or third-line treatment. A cohort of patients starting second or third-line nivolumab for advanced cancer from 2016 to 2018 was identified from our institution IRB approved and prospectively collected registry. HPD was defined as at least two-fold increase in the tumor growth rate (TGR) during immunotherapy compared to TGR during the preimmunotherapy period. Overall, 47 patients were eligible for this analysis. HPD was observed in three patients (6%) with metastatic lung adenocarcinoma, metastatic urothelial transitional carcinoma, and metastatic hepatocellular carcinoma, respectively. These three patients showed a rapid clinical deterioration and survived less than 3.5 months from immunotherapy onset. Their chief preimmunotherapy characteristics were: age < 75 years, >= 2 metastatic sites, programmed death-ligand 1 < 50%, neutrophil-to-lymphocyte ratio > 3, and elevated lactate dehydrogenase. The results of the current study seem to reinforce the hypothesis that in some cases immunotherapy promotes a dramatic increase of TGR and may suggest possible clinical predictors of HPD during nivolumab.
Details
- Title: Subtitle
- Hyperprogressive disease in advanced cancer patients treated with nivolumab: a case series study
- Creators
- Roberto Petrioli - University of SienaMaria Antonietta Mazzei - Azienda Osped Univ Senese, Dept Med Surg & Neuro Sci, Diagnost Imaging, Siena, ItalySilvano Giorgi - Azienda Ospedaliera Universitaria SeneseEleonora Cesqui - Azienda Ospedaliera Universitaria SeneseFrancesco Gentili - Azienda Osped Univ Senese, Dept Med Surg & Neuro Sci, Diagnost Imaging, Siena, ItalyGuido Francini - Azienda Osped Univ Senese, Dept Med Surg & Neurosci, Med Oncol Unit, Siena, ItalyLuca Volterrani - Azienda Osped Univ Senese, Dept Med Surg & Neuro Sci, Diagnost Imaging, Siena, ItalyEdoardo Francini - Ospedale Misericordia - Grosseto
- Resource Type
- Journal article
- Publication Details
- Anti-cancer drugs, Vol.31(2), pp.190-195
- DOI
- 10.1097/CAD.0000000000000864
- PMID
- 31850916
- ISSN
- 0959-4973
- eISSN
- 1473-5741
- Publisher
- Lippincott Williams & Wilkins
- Number of pages
- 6
- Language
- English
- Date published
- 02/01/2020
- Academic Unit
- Internal Medicine
- Record Identifier
- 9985221147002771
Metrics
1 Record Views